吉非替尼联合培美曲塞+顺铂化疗方案在晚期表皮生长因子受体敏感突变肺癌患者中的应用效果  

Effect of Gefitinib combined with Pemetrexed + Cisplatin in patients with advanced epidermal growth factor receptor-sensitive mutated lung cancer

作　　者：李娥梅 颜志婷 占志强[1] 曾艳红[1] LI Emei;YAN Zhiting;ZHAN Zhiqiang;ZENG Yanhong(Department of Pharmacy,Pingxiang People's Hospital,Jiangxi Province,Pingxiang337000,China)

机构地区：[1]江西省萍乡市人民医院药学部,江西萍乡337000

出　　处：《中国当代医药》2023年第2期153-155,共3页China Modern Medicine

基　　金：江西省萍乡市科技计划项目(2021PY086)。

摘　　要：目的探讨吉非替尼联合培美曲塞+顺铂化疗方案(PP化疗方案)在晚期表皮生长因子受体(EGFR)敏感突变肺癌患者中的应用效果。方法选取2019年1月至2022年3月萍乡市人民医院收治的140例晚期EGFR敏感突变肺癌患者为研究对象,采用随机数字表法分为观察组和对照组,每组各70例。对照组使用吉非替尼治疗,观察组在对照组基础上加用PP化疗方案。比较两组患者的临床疗效、肿瘤标志物水平、不良反应。结果观察组的疾病控制率、治疗总有效率均高于对照组,差异有统计学意义(P<0.05)。糖类抗原125(CA-125)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)水平低于对照组,差异有统计学意义(P<0.05)。两组患者的各项不良反应发生率比较,差异无统计学意义(P>0.05)。结论吉非替尼联合PP化疗方案治疗晚期EGFR敏感突变肺癌疗效显著,可改善肿瘤标志物水平,且未明显增加不良反应,可推广。Objective To observe the effect of Gefitinib combined with Pemetrexed+Cisplatin(PP chemotherapy regimen)in patients with advanced epidermal growth factor receptor(EGFR)-sensitive mutated lung cancer.Methods A total of 140 patients with advanced EGFR-sensitive mutant lung cancer who were admitted to the Pingxiang People's Hospital from January 2019 to March 2022 were selected as the research subjects,they were divided into observation group and control group by random number table method,with 70 patients in each group.Patients in the control group were treated with Gefitinib,and those in the observation group were treated with PP chemotherapy on this basis.Clinical effect,tumor marker levels,and toxicity were compared between the groups.Results The disease control rate and total effective rate of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).The levels of carbohydrate antigen 125(CA-125),carcinoembryonic antigen(CEA)and neuron specific enolase(NSE)were lower than those of control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion Gefitinib combined with PP chemotherapy regimen is effective in the treatment of advanced EGFR-sensitive mutant lung cancer.It can improve tumor marker levels,without increasing toxicity.

关 键 词：吉非替尼 培美曲塞+顺铂化疗方案 晚期肺癌 肿瘤标志物 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]